Abbott sets up barriers against unfriendly takeover
This article was originally published in Clinica
Executive Summary
Weakened by a succession of bad news which has driven down its share price, Abbott Laboratories has put in place a shareholder rights plan designed to make the company impossibly expensive to an unfriendly buyer. The so-called "poison pill" comes as the pharmaceutical industry engages in an orgy of takeovers - Abbott's shares have fallen 24% this year.